Your browser doesn't support javascript.
loading
ecTMB: a robust method to estimate and classify tumor mutational burden.
Yao, Lijing; Fu, Yao; Mohiyuddin, Marghoob; Lam, Hugo Y K.
Afiliación
  • Yao L; Roche Sequencing Solutions, Santa Clara, CA, 95050, USA.
  • Fu Y; Roche Sequencing Solutions, Santa Clara, CA, 95050, USA.
  • Mohiyuddin M; Roche Sequencing Solutions, Santa Clara, CA, 95050, USA.
  • Lam HYK; Roche Sequencing Solutions, Santa Clara, CA, 95050, USA. bioinformatics.red@roche.com.
Sci Rep ; 10(1): 4983, 2020 03 18.
Article en En | MEDLINE | ID: mdl-32188929
Tumor Mutational Burden (TMB) is a measure of the abundance of somatic mutations in a tumor, which has been shown to be an emerging biomarker for both anti-PD-(L)1 treatment and prognosis; however, multiple challenges still hinder the adoption of TMB as a biomarker. The key challenges are the inconsistency of tumor mutational burden measurement among assays and the lack of a meaningful threshold for TMB classification. Here we describe a new method, ecTMB (Estimation and Classification of TMB), which uses an explicit background mutation model to predict TMB robustly and to classify samples into biologically meaningful subtypes defined by tumor mutational burden.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: ADN de Neoplasias / Biomarcadores de Tumor / Genoma Humano / Carga Tumoral / Mutación / Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: ADN de Neoplasias / Biomarcadores de Tumor / Genoma Humano / Carga Tumoral / Mutación / Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos